Skip to main content

Table 4 Designated and estimated prevalence of HPV18 by Linear Assay (LA)-only and sequential testing strategies in the United States and Latin America

From: Comparison of DNA testing strategies in monitoring human papillomavirus infection prevalence through simulation

Genotyping assay performance Time Designated composite prevalence (SD) LA only Sequential testing
Composite prevalence estimate (SD) Estimate-to-true ratio Composite prevalence estimate (SD) Estimate-to-true ratio
United States
Sen = 1.00
Spe = 1.00
Baseline 0.019 (0.002) 0.019 (0.002) 1.000 0.003 (0.001) 0.158
Reduced 0.009 (0.002) 0.009 (0.002) 1.000 0.002 (0.001) 0.222
% Reduction 52 52   33  
Sen = 0.95
Spe = 0.95
Baseline 0.019 (0.002) 0.067 (0.004) 3.526 0.020 (0.002) 1.053
Reduced 0.009 (0.002) 0.058 (0.004) 6.444 0.017 (0.002) 1.889
% Reduction 52 13.4   15  
Sen = 0.95
Spe = 0.90
Baseline 0.019 (0.002) 0.116 (0.005) 6.105 0.043 (0.003) 2.263
Reduced 0.009 (0.002) 0.108 (0.005) 12.000 0.040 (0.003) 4.444
% Reduction 52 6.9   7  
Sen = 0.90
Spe = 0.90
Baseline 0.019 (0.002) 0.115 (0.005) 6.052 0.042 (0.003) 2.210
Reduced 0.009 (0.002) 0.107 (0.005) 11.889 0.039 (0.003) 4.333
% Reduction 52 7.0   7.1  
Sen = 0.90
Spe = 0.85
Baseline 0.019 (0.002) 0.164 (0.006) 8.632 0.066 (0.004) 3.474
Reduced 0.009 (0.002) 0.157 (0.006) 17.444 0.064 (0.004) 7.111
% Reduction 52 4.3   3.0  
Sen = 0.85
Spe = 0.85
Baseline 0.019 (0.002) 0.163 (0.006) 8.579 0.066 (0.004) 3.474
Reduced 0.009 (0.002) 0.156 (0.006) 17.33 0.063 (0.004) 7.000
% Reduction 52 4.3   4.5  
Sen = 0.80
Spe = 0.80
Baseline 0.019 (0.002) 0.211 (0.006) 11.105 0.090 (0.004) 4.737
Reduced 0.009 (0.002) 0.206 (0.006) 22.889 0.088 (0.005) 9.778
% Reduction 52 2.3   2.2  
Latin America       
Sen = 1.00
Spe = 1.00
Baseline 0.012 (0.002) 0.012 (0.002) 1.000 0.003 (0.001) 0.250
Reduced 0.006 (0.002) 0.006 (0.002) 1.000 0.001 (0.001) 0.167
% Reduction 50 50   50  
Sen = 0.95
Spe = 0.95
Baseline 0.012 (0.002) 0.061 (0.004) 5.083 0.016 (0.002) 1.333
Reduced 0.006 (0.002) 0.056 (0.004) 9.333 0.015 (0.002) 2.500
% Reduction 50 8.2   6.3  
Sen = 0.95
Spe = 0.90
Baseline 0.012 (0.002) 0.110 (0.005) 9.167 0.039 (0.003) 3.250
Reduced 0.006 (0.001) 0.105 (0.005) 17.500 0.037 (0.003) 6.167
% Reduction 50 4.5   5.1  
Sen = 0.90
Spe = 0.90
Baseline 0.012 (0.002) 0.109 (0.005) 9.083 0.039 (0.003) 3.250
Reduced 0.006 (0.001) 0.105 (0.005) 17.500 0.037 (0.003) 6.167
% Reduction 50 3.7   5.1  
Sen = 0.90
Spe = 0.85
Baseline 0.012 (0.002) 0.159 (0.006) 13.250 0.063 (0.004) 5.250
Reduced 0.006 (0.001) 0.154 (0.006) 25.667 0.062 (0.004) 10.333
% Reduction 50 3.1   1.6  
Sen = 0.85
Spe = 0.85
Baseline 0.012 (0.002) 0.158 (0.006) 13.167 0.063 (0.004) 5.250
Reduced 0.006 (0.001) 0.154 (0.005) 25.667 0.061 (0.004) 10.166
% Reduction 50 3.1   3.1  
Sen = 0.80
Spe = 0.80
Baseline 0.012 (0.002) 0.207 (0.006) 17.250 0.087 (0.004) 7.250
Reduced 0.006 (0.001) 0.204 (0.006) 34.000 0.086 (0.004) 14.333
% Reduction 50 1.1   1.1  
  1. Type-specific prevalence at baseline, in the US: HPV18 = 0.019; in Latin America: HPV18 = 0.012
  2. Reduced: HPV18 is reduced by 50 %
  3. Abbreviations: SD standard deviation, Sen sensitivity, Spe specificity